程序性死亡蛋白-1/程序性死亡蛋白配体-1抑制剂治疗食管癌的进展

Progress of programmed death-1/programmed death ligand-1 inhibitors for esophageal cancer

免疫治疗是现今肿瘤治疗的重要方式,其中程序性死亡蛋白-1/程序性死亡蛋白配体-1抑制剂是目前应用较为成熟且患者生存获益较大的免疫制剂。程序性死亡蛋白-1/程序性死亡蛋白配体-1抑制剂给食管癌患者带来更好的临床获益,也为食管癌的治疗提供了更有利的选择。该文介绍了程序性死亡蛋白-1/程序性死亡蛋白配体-1抑制剂的作用机制、在食管癌中的应用以及疗效预测指标,旨在为程序性死亡蛋白-1/程序性死亡蛋白配体-1抑制剂更合理地用于食管癌提供一定理论基础。

Immunotherapy is an important treatment method in tumor therapy.Among them,programmed death-1/programmed death ligand-1 inhibitors are the immune preparations with mature application and great survival benefit at present.Programmed death-1/programmed death ligand-1 inhibitors brought better clinical benefits to patients with esophageal cancer and provided more favorable choice for the treatment of esophageal cancer.This article introduces the mechanism of action,application in esophageal cancer,and efficacy predictors of programmed death protein-1/programmed death protein ligand-1 inhibitors,aiming to provide a theoretical basis for the more rational use of programmed death protein-1/programmed death protein ligand-1 inhibitors in patients with esophageal cancer.